BriaCell Therapeutics Corp. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BCTX Nasdaq 2836 briacell.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BriaCell Therapeutics Corp.

BriaCell Therapeutics Announces Closing of $15 million Public Offering - Jul 16th, 2025 2:05 pm
BriaCell Therapeutics Announces Pricing of $15 million Public Offering - Jul 15th, 2025 1:05 pm
BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer - Jul 15th, 2025 5:30 am
BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer - Jul 11th, 2025 5:30 am
BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient - Jul 10th, 2025 5:30 am
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study - Jul 9th, 2025 5:30 am
BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer - Jul 8th, 2025 5:30 am
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven - Jul 2nd, 2025 5:30 am
Here's Why We're A Bit Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation - Jun 25th, 2025 6:11 am
BriaCell Up in U.S. Pre-market, as Data Safety Board Review Recommends Phase 3 Study Continues - Jun 24th, 2025 6:52 am
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer - Jun 24th, 2025 5:30 am
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26 - Jun 4th, 2025 5:30 am
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025 - Jun 2nd, 2025 5:30 am
BriaCell Down More Than 2% Even As Says Bria-OTS Phase 1/2 Study Clears Safety Evaluation; First Patient Dosed - May 27th, 2025 8:25 am
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor - May 27th, 2025 5:30 am
BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025 - May 23rd, 2025 5:30 am
BriaCell CEO Letter to Shareholders - May 20th, 2025 5:30 am
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified - Apr 30th, 2025 5:30 am
BriaCell Therapeutics Announces Closing of $13.8 million Public Offering - Apr 28th, 2025 2:05 pm
BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development - Apr 28th, 2025 5:30 am